All In Biotech

Drug Trial Radar · NCT05257083

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 759 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

759

Actual

Start

Oct 10, 2023

Primary completion

Jun 2033

Study completion Aug 2040

Sponsor

Lead sponsor
Stichting European Myeloma NetworkResearch network
Sponsor type
Research network
Collaborators
Janssen Research & Development, LLC
First posted
Feb 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.

Conditions

  • Multiple Myeloma

Interventions

  • DaratumumabDrug

    Daratumumab will be administered SC.

  • BortezomibDrug

    Bortezomib will be administered SC.

  • LenalidomideDrug

    Lenalidomide will be administered orally.

  • DexamethasoneDrug

    Dexamethasone will be administered orally.

  • Cilta-celDrug

    Cilta-cel will be administered intravenously

  • CyclophosphamideDrug

    Cyclophosphamide will be administered intravenously.

  • FludarabineDrug

    Fludarabine will be administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: up to 10 years ( or 300 PFS events)
  2. Sustained MRD-negative CRTime frame: up to 24 months

Locations

106 sites in 16 countries. Site status is shown where the registry gives one.

  • University of Arkansas

    Little Rock, Arkansas

  • City of Hope

    Duarte, California

  • UC San Diego Health Moores Cancer Center

    San Diego, California

  • University of California San Francisco (UCSF)

    San Francisco, California

  • Stanford University

    Stanford, California

  • Moffit Cancer Center

    Tampa, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University Of Maryland Medical Center

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Center

    Detroit, Michigan

  • Mount Sinai Medical Center

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • Montefiore M-E Center

    The Bronx, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Virginia

    Charlottesville, Virginia

  • University of Washington Medical

    Seattle, Washington

  • Medical College Wisconsin

    Milwaukee, Wisconsin

  • Princess Alexandra Hospital

    Brisbane, Australia

  • Royal Prince Alfred Hospital

    Camperdown, Australia

  • Royal Brisbane and Womens Hospital

    Herston, Australia

  • Alfred Health

    Melbourne, Australia

  • Austin Hospital

    Melbourne, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • Fiona Stanley Hospital

    Murdoch, Australia

  • Calvary Mater Newcastle Hospital

    Waratah, Australia

  • Westmead Hospital

    Westmead, Australia

  • Jules Bordet Instituut

    Anderlecht, Belgium

  • UZA

    Antwerp, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.